ClinicalTrials.gov
ClinicalTrials.gov Menu

Un-fractionated Heparin Versus Bivalirudin During Percutaneous Coronary Interventions (PCI) (ISAR-REACT-3)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00262054
Recruitment Status : Completed
First Posted : December 6, 2005
Last Update Posted : March 15, 2010
Sponsor:
Information provided by:
Deutsches Herzzentrum Muenchen

December 5, 2005
December 6, 2005
March 15, 2010
November 2005
February 2008   (Final data collection date for primary outcome measure)
Composite rate of death, myocardial infarction (MI),urgent target vessel revascularization (TVR) within 30 days or in-hospital major bleeding [ Time Frame: 30 days ]
  • Composite rate of death, myocardial infarction (MI),
  • urgent target vessel revascularization (TVR) within 30 days or in-hospital major bleeding
Complete list of historical versions of study NCT00262054 on ClinicalTrials.gov Archive Site
  • Composite rate of death, MI or urgent TVR within 30 days [ Time Frame: 30 days ]
  • Composite rate of death, MI or TVR at 1 year [ Time Frame: 1 year ]
  • Composite rate of death, MI or urgent TVR within 30 days
  • Composite rate of death, MI or TVR at 1 year
Not Provided
Not Provided
 
Un-fractionated Heparin Versus Bivalirudin During Percutaneous Coronary Interventions (PCI) (ISAR-REACT-3)
Prospective, Randomized, Double-Blind, Active-Controlled, Multicenter Trial of Bivalirudin and Un-fractionated Heparin in Patients Undergoing Percutaneous Coronary Interventions. ISAR-REACT-3
The purpose of this study is to determine whether bivalirudin given during PCI is associated with better outcomes compared to un-fractionated heparin.
Thrombin plays a major role in acute coronary artery occlusions during percutaneous coronary interventions. Unfractionated heparin has been traditionally used during invasive coronary procedures to reduce the risk of thrombotic occlusion. Bivalirudin, a direct antithrombin inhibitor, has several advantages over unfractionated heparin: it acts independently of antithrombin and inhibits both free and clot-bound thrombin; it is not neutralized by circulating inhibitors; exhibits consistent dose-response characteristics, and does not cause thrombocytopenia. Previous studies have shown that use of bivalirudin among patients undergoing percutaneous coronary interventions is associated with better outcomes (death, myocardial infarction, urgent repeat revascularization or in-hospital major bleeding) as compared with unfractionated heparin and adjunctive use of glycoprotein IIb/IIIa platelet receptor inhibitors. However, previous studies have included patients treated with plain balloon angioplasty or stenting after inadequate pre-treatment with thienopyridines (ticlopidine or clopidogrel). Recent guidelines recommend that all patients undergoing percutaneous coronary interventions must receive a loading dose of 300 -600 mg of clopidogrel. A 600 mg loading dose of clopidogrel eliminates the need for glycoprotein IIb/IIIa platelet receptor inhibitors in adjunct to heparin. According to existing evidence antithrombotic regimens based on either bivalirudin or pre-treatment with 600 mg of clopidogrel in addition to UFH intraprocedurally, are effective strategies to reduce ischemic and hemorrhagic complications in patients with coronary artery disease undergoing PCI. At present, it is not known whether bivalirudin is superior to UHF in patients who have been optimally pre-treated with a loading dose of clopidogrel.
Interventional
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Coronary Disease
  • Angina Pectoris
  • Drug: Bivalirudin
    bivalirudin to be administered as an intravenous bolus of 0.75 mg/kg prior to the start of the intervention, followed by infusion of 1.75 mg/kg per hour for the duration of the procedure.
    Other Name: ReoPro
  • Drug: Un-fractionated heparin
    UFH is given as an intravenous bolus of 140 units/kg followed by infusion of placebo 1.75 mg/kg per hour for the duration of the procedure.
  • Experimental: A
    bivalirudin is to be administered as an intravenous bolus of 0.75 mg/kg prior to the start of the intervention, followed by infusion of 1.75 mg/kg per hour for the duration of the procedure.
    Intervention: Drug: Bivalirudin
  • Active Comparator: B
    UFH given as an intravenous bolus of 140 units/kg. Double blinding will be maintained by using a double-dummy technique consisting of identical UFH and bivalirudin syringes and bivalirudin or placebo infusion bags.
    Intervention: Drug: Un-fractionated heparin

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
4570
3000
May 2008
February 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients older than 18 years of age to undergo PCI
  • Clopidogrel loading at least 2 hrs prior to PCI according to the PCI guidelines
  • Informed, written consent

Exclusion Criteria:

  • Recent ST-elevation myocardial infarction within the last 48 hours
  • Cardiogenic shock
  • ACS and positive biomarkers (Troponin T > 0.03 µg/L)
  • Malignancies or other comorbid conditions (for example severe liver, renal and pancreatic disease) with life expectancy less than one year or that may result in protocol non-compliance
  • Active bleeding; bleeding diathesis
  • History of gastrointestinal or genitourinary bleeding within the last 6 weeks
  • Presence of diseases which have a high probability of vascular lesions and subsequent bleeding such as active gastric ulcer or active ulcerous colitis
  • Recent trauma or major surgery in the last month
  • Ophthalmic surgery or brain surgery in the last month
  • Retinopathies or vitreous body bleeding in the last month
  • History of intracranial bleeding or structural abnormalities (for example aneurysm of cerebral arteries)
  • Suspected aortic dissection; pericarditis and subacute bacterial endocarditis
  • Patient's refusal to blood transfusion
  • Oral anticoagulation therapy with coumarin derivative within the last 7 days
  • Treatment with UFH within 6 hours or low-molecular weight heparin within 8 hours before randomization
  • Treatment with bivalirudin within 24 hours before randomization
  • Severe uncontrolled hypertension >180/110 mmHg unresponsive to therapy
  • Planned staged PCI procedure within 30 days from index procedure or prior PCI within the last 30 days
  • Relevant hematologic deviations:hemoglobin < 100 g/L; platelet count < 100 x 109 /L
  • Glomerular filtration rate (GFR) < 30 ml/min or serum creatinine > 30 mg/L or dependence on renal dialysis
  • Known allergy to the study medications: aspirin, clopidogrel, UFH, bivalirudin; stainless steel; true anaphylaxis after prior exposure to contrast media
  • Known heparin-induced thrombocytopenia (Typ II)
  • Previous enrollment in this trial
  • Pregnancy (present, suspected or planned) or positive pregnancy test
  • Spinal, peridural and epidural anesthesia
  • Patient's inability to fully cooperate with the study protocol
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
 
NCT00262054
GE IDE No. A01005
KKF 1.1-05
Yes
Not Provided
Not Provided
Prof. A. Schömig, Deutsches Herzzentrum Munich
Deutsches Herzzentrum Muenchen
Not Provided
Study Chair: Albert Schomig, MD Deutsches Herzzentrum Muenchen
Principal Investigator: Adnan Kastrati, MD Deutsches Herzzentrum Muenchen
Study Director: Franz-Josef Neumann, MD Herz-Zentrum Bad Krozingen
Deutsches Herzzentrum Muenchen
August 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP